European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies

Descripción del proyecto

DE EN ES FR IT PL

Imagenología para evaluar el estado inmunitario del paciente

La inmunoterapia puede tratar de forma eficaz varias enfermedades graves, como el cáncer y las enfermedades inflamatorias, pero la clave está en el enfoque personalizado. La combinación de los marcadores sanguíneos y tisulares con la imagenología no invasiva podría ayudar a evaluar el estado inmunitario «in vivo», pero es una opción que apenas se ha explorado. Para ello, el proyecto Immune-Image, financiado con fondos europeos, desarrollará rastreadores inmunológicos para tomar imágenes de subconjuntos específicos de células inmunitarias y luego validarlos en los modelos pertinentes de enfermedades. El objetivo es fabricarlos y luego realizar ensayos clínicos inteligentes. Este consorcio internacional multidisciplinar trabajará en la optimización de las técnicas de imagenología molecular para evaluar el estado inmunitario del paciente mediante rastreadores inmunológicos y para desarrollar fármacos inmunoterapéuticos personalizados.

Objetivo

Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers.
To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions.
To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

H2020-JTI-IMI2-2018-14-two-stage

Consulte otros proyectos de esta convocatoria

Régimen de financiación

RIA - Research and Innovation action

Coordinador

STICHTING AMSTERDAM UMC
Aportación neta de la UEn
€ 3 993 722,00
Dirección
DE BOELELAAN 1117
1081 HV Amsterdam
Países Bajos

Ver en el mapa
Región
West-Nederland Noord-Holland Groot-Amsterdam
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 5 390 722,50

Participantes (24)

Compartir esta página

Descargar

Última actualización: 24 Junio 2024

Mi folleto

Permalink: https://cordis.europa.eu/project/id/831514/es

European Union, 2024